Inactive/Delisted stock

Sunshine Biopharma Stock (NASDAQ:SBFM)


Chart

Previous Close

$2.34

52W Range

$2.02 - $266.00

50D Avg

$2.71

200D Avg

$4.32

Market Cap

$6.47M

Avg Vol (3M)

$93.72K

Beta

-1.48

Div Yield

-

SBFM Company Profile


Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

44

IPO Date

Feb 15, 2022

Website

SBFM Performance


Peer Comparison


TickerCompany
SXTCChina SXT Pharmaceuticals, Inc.
EGRXEagle Pharmaceuticals, Inc.
ALIMAlimera Sciences, Inc.
PAHCPhibro Animal Health Corporation
SNOASonoma Pharmaceuticals, Inc.
GHSIGuardion Health Sciences, Inc.